ArticleBiometrics2007
Bayesian inference for the lead time in periodic cancer screening.
Article in Biometrics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement.American journal of respiratory and critical care medicine · 2017Guideline
- Evaluating Semi-Markov Processes and Other Epidemiological Time-to-Event Models by Computing Disease Sojourn Density as Partial Differential Equations.Medical decision making : an international journal of the Society for Medical Decision Making · 2025Article
- Evaluation of the Slovenian Breast Cancer Screening Programme: Years of Life Gained and Avoided Deaths.Cancers · 2025Article
- When to initiate cancer screening exam?Statistics and its interface · 2022Article
- Estimation of Lead Time via Low-Dose CT in the National Lung Screening Trial.Journal of healthcare informatics research · 2018Article
- Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.World journal of gastroenterology · 2015Article
- Bayesian lead time estimation for the Johns Hopkins Lung Project data.Journal of epidemiology and global health · 2013Article
- Sojourn time and lead time projection in lung cancer screening.Lung cancer (Amsterdam, Netherlands) · 2011Article
- Inferences for the Lead Time in Breast Cancer Screening Trials under a Stable Disease Model.Cancers · 2011Article
- Estimating key parameters in periodic breast cancer screening-application to the Canadian National Breast Screening Study data.Cancer epidemiology · 2010Article
- A projection of benefits due to fecal occult blood test for colorectal cancer.Cancer epidemiology · 2009Article
- How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening.Medical decision making : an international journal of the Society for Medical Decision MakingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This article develops a probability distribution for the lead time in periodic cancer screening examinations. The general aim is to allow statistical inference for a screening program's lead time, the length of time the diagnosis is advanced by screening. The program's lead time is distributed as a mixture of a point mass and a piecewise continuous distribution. Simulation studies using the HIP (Health Insurance Plan for Greater New York) study's data provide estimates of different characteristics of a screening program under different screening frequencies. The components of this mixture represent two aspects of screening's benefit, namely, a reduction in the number of interval cases and the extent by which screening advanced the age of diagnosis. We present estimates of these two measures for participants in a breast cancer screening program. We also provide the mean, mode, variance, and density curve of the program's lead time. The model can provide policy makers with important information regarding the screening period, frequency, and the endpoints that may serve as surrogates for the benefit to women who take part in a periodic screening program. Though the study focuses on breast cancer screening, it is also applicable to other kinds of chronic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.